Last Updated on June 28, 2024 by The Health Master
Form 483
Biotechnology leader Biocon Ltd. announced that the U.S. Food and Drug Administration (USFDA) conducted a Good Manufacturing Practice (GMP) inspection of their Active Pharmaceutical Ingredient (API) facility (Site 5) located in Visakhapatnam, Andhra Pradesh, concluding on June 21, 2024 and issued Form 483.
Four Observations Noted by USFDA
Following the inspection, the USFDA issued a Form 483 to Biocon, outlining four observations.
These observations detail potential non-compliance issues that could impact the facility’s adherence to the Food, Drug, and Cosmetic (FD&C) Act.
Biocon has assured investors that they will address these observations within the timeframe stipulated by the USFDA.
What is a Form 483?
A Form 483 is an official document used by the USFDA to communicate its observations of potential violations during a GMP inspection.
It serves as a notification to the inspected firm’s management, highlighting areas where practices or conditions may not meet the established regulatory requirements.
What Happens Next?
Biocon will now initiate a comprehensive process to address the observations outlined in the Form 483.
This will likely involve a detailed investigation of each observation, followed by the implementation of corrective and preventive actions (CAPAs) to ensure compliance with USFDA regulations.
Biocon will then submit a written response to the USFDA, outlining the specific actions taken to address each observation.
Importance of GMP Compliance for Biocon
Maintaining GMP compliance is crucial for Biocon’s continued success in the global pharmaceutical market.
These regulations ensure the quality, safety, and efficacy of their API products.
A successful resolution of the observations outlined in the Form 483 will minimize potential disruptions to Biocon’s manufacturing operations and ensure continued trust from their customers and regulatory bodies.
Investors Advised to Monitor the Situation
While receiving a Form 483 is not uncommon during routine inspections, it’s important for investors to stay informed about the developments.
Biocon is expected to provide further updates on their progress in addressing the USFDA observations.
Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.
USFDA issues Form 483 with 6 observations to Cipla for Goa facility
USFDA inspection concluded at Lupin with zero observations
USFDA issues Form 483 with 5 observations to Torrent Pharma
USFDA issues Form 483 with 4 observations to Dr. Reddy’s
USFDA issues OAI status to Eugia Pharma of Aurobindo
USFDA inspection concluded at Solara Pharma without any observations
Drug recall: Lupin, Eugia recalled products Due to Manufacturing Issues
Exploring Himachal Pradesh’s New Bulk Drug Park
Drug alert: 52 drug samples declared as NSQ in May 2024
Nutraceutical Manufacturing in Drug Facilities: 5 members committee formed
USFDA issues Form 483 with 6 observations to Cipla for Goa facility
Drug Bust in Patna: Crackdown on Illegal Cough Syrups Trade
Inclusion of Pharmacy Subject in Civil Services Exams gains Momentum
OTC sale of MTP Kits banned: Karnataka
USFDA issues warning letter to Sun Pharma for Dadra Unit
MN Sridhar appointed as State Licensing and Controlling Authority of Tamil Nadu
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
